Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.

Lucia VietriPaolo CameliMarco PerruzzaBehar CekorjaLaura BergantiniMiriana d'AlessandroRosa Metella RefiniMaria PieroniAntonella FossiDavid BennettMarco SpallettiMaria Antonietta MazzeiPiersante SestiniPaola RottoliElena Bargagli

Published in: Therapeutic advances in respiratory disease (2021)

Our findings confirm the efficacy of pirfenidone in reducing functional progression of IPF and its excellent safety profile in a real-life setting. This study, designed on a long-term follow up, contributes to the growing evidence on safety, tolerability and efficacy of pirfenidone in IPF. The reviews of this paper are available via the supplemental material section.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
primary care
open label
randomized controlled trial
systematic review
clinical trial
rheumatoid arthritis
study protocol